An effective and safe targeted therapy for treatment of Myasthenia gravis
|Funding from Vinnova||SEK 500 000|
|Project duration||December 2018 - August 2019|
Purpose and goal
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease with a huge unmet need for new effective and safe therapies as current treatment options are only symptomatic and are accompanied by severe side effects. Toleranzia is developing TOL2, a disease-specific drug for treatment of MG. TOL2 has an extraordinary long-lasting therapeutic effect shown in an animal model of MG and could become the first tolerance-inducing therapy in the market. In the proposed project, we will set up and execute a complete feasibility study to assess the potential of TOL2 to reach the market.
Expected results and effects
The feasibility study will include an in-depth market study to further decipher risks and potential entry barriers due to market acceptance and regulations. Moreover, a careful study to further secure IP as well as a business plan will be developed. The results of this project will provide Toleranzia with the necessary resources to effectively implement a high-quality application within the SME Instrument Phase 2 program.
Planned approach and implementation
The project will have a duration of six months. Based on our current organization, four people will lead the main areas of the project, applying our established project management structure (integrated weekly meetings, web-based system for effective and safe document handling, fluid communication among project members and early detection of issues and risks).